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Exogenous Addition of 25-Hydroxycholesterol Reduces
Level of Very Long-Chain Fatty Acids in X-Linked
Adrenoleukodystrophy
Jiho Jang,*[a] Jung Wuk Lee,[b] Jiho Song,[b] Dong-Wook Kim,[a] and Kyung Hoon Min*[b]
X-Linked adrenoleukodystrophy (X-ALD) is a severe metabolic
disorder characterized by the accumulation of very long-chain
fatty acids (VLCFAs). Recently, we demonstrated that levels of
25-hydroxycholesterol (25-HC) and cholesterol 25-hydroxylase
(CH25H) were found to be elevated in X-ALD. Herein, we report
that the exogenous addition of 25-HC significantly reduces
C26:0 levels in X-ALD patient-derived fibroblasts and oligoden-
drocytes differentiated from induced pluripotent stem cells
(iPSCs) derived from X-ALD patients. Moreover, 25-HC treatment
was found to down-regulate the expression of ELOVL1, a key
enzyme for the synthesis of C26. In addition, activation of liver
X receptor (LXR), a molecular target of endogenous 25-HC, also
reduced C26:0 level. The reduction of C26:0 levels by 25-HC
treatment might result, at least partially, from the decrease of
ELOVL1 expression as well as the activation of LXR. Our findings
could provide a better understanding of the role of 25-HC in X-
ALD and useful information to find therapeutic agents to treat
X-ALD.
Aberrant accumulation of very long chain fatty acids (VLCFA, �
C24:0), resulting from mutation of ATP-binding cassette trans-
porter subfamily D member 1 (ABCD1), is a key feature of X-
linked adrenoleukodystrophy (X-ALD).[1,2] It has been reported
that due to the impaired peroxisomal β-oxidation of VLCFAs,
C26:0 and C24:0 levels were 4–6 fold and 10–30% higher in
fibroblasts from patients with X-ALD, respectively, compared to
controls, whereas C22:0 levels were unaffected.[3–5] VLCFA
accumulation is critically involved in the process of tissue
damage.[1,2] Therefore, prevention of VLCFA accumulation can
be an effective treatment for X-ALD. Lorenzo’s oil has been
used as a dietary supplement in patients with X-ALD. However,
it does neither affect C26:0 levels in the nervous system, nor
prevent disease progression.[6,7] Lovastatin, a potent HMG-CoA
reductase inhibitor, was also a high potential candidate to
overcome X-ALD.[8,9] However, it did not show a significant
reduction in C26:0 in a randomized, double-blind clinical trial.[10]
To date, there are no clinically useful approaches to sufficiently
reduce VLCFA levels to inhibit X-ALD progression.
Recently, we demonstrated that upregulation of a cholester-
ol metabolite, 25-hydroxycholesterol (25-HC) and its synthesiz-
ing enzyme, cholesterol 25-hydroxylase (CH25H), was observed
in Childhood Cerebral Adrenoleukodystrophy (CCALD) patients-
derived cells and ex vivo.[11] Further, dysfunction of ABCD1 is
implicated in the induction of CH25H expression.[11] Moreover, it
was reported that 25-HC is a factor contributing to neuro-
inflammation in X-ALD.[11]
25-HC has been identified as a key regulator of lipid
metabolism.[12] It also has been demonstrated that 25-HC acts as
an intrinsic lipid effector of the interferon antiviral response and
suppresses viral infection for a broad range of viruses including
zika virus.[13–16] In addition, 25-HC significantly reduced LPS-
induced inflammatory response through interaction with
myeloid differentiation protein 2.[17]
In this study, we have undertaken further investigation on
the pathophysiological role of 25-HC in X-ALD and revealed
significant reduction of VLCFA (C26:0) by exogenous addition of
25-HC.
Exogenous addition of 25-HC significantly reduced the level
of VLCFA in CCALD patient-derived fibroblasts (CCALD-fibro-
blast), as shown in Figure 1. When CCALD-fibroblasts were
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Figure 1. Changes in C26:0/C22:0 by 25-HC treatment. a) C26:0/C22:0 ratio
was reduced by adding 25-HC at indicated concentrations in CCALD and
AMN fibroblasts. b) Addition of 25-HC reduced the level of C26:0/C22:0 ratio
in oligodendrocytes differentiated from patient-derived iPS cells. The
fibroblasts and oligodendrocytes were treated with 25-HC for 3 days. Data
are shown as mean from three independent experiments �S.D. (n=3).
*p<0.05, **p<0.01, one-way ANOVA with Tukey’s post-hoc test.
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treated with 1 μM of 25-HC, significant reduction of C26:0/C22:0
ratio was observed. Further, the VLCFA levels decreased in a
concentration-dependent manner, such that the higher the
concentration of 25-HC, the greater the decrease in VLCFA
levels. This reduction in VLCFA by 25-HC addition was
consistently observed in adrenomyeloneuropathy (AMN) pa-
tient-derived fibroblasts and oligodendrocytes (CCALD-oligo-
dendrocytes) differentiated from induced pluripotent stem cells
(iPSC) derived from CCALD patients.
To determine the effect of endogenous 25-HC on VLCFA
levels, CH25H overexpression and knockdown experiments
were conducted in CCALD- and AMN-fibroblasts. As shown in
Figure 2, ectopic expression of CH25H led to a slight decrease of
VLCFA. The overexpression of CH25H did not result in great
changes in the VLCFA level as compared to exogenous addition
of 1 μM 25-HC, showing approximately 10% and 30% reduc-
tions, respectively. As such, it seems that 25-HC itself affects
VLCFA production more than CH25H. In contrast, knock-down
of CH25H using siRNA resulted in significant increases of VLCFA.
These data suggest that endogenous 25-HC may contribute to
suppression of VLCFA accumulation. However, increased levels
of VLCFA are observed in X-ALD fibroblasts although 25-HC is
upregulated.[11] This is possibly because 25-HC concentrations
may not be elevated sufficiently to reduce VLCFA levels.
Alternatively, part of the endogenous 25-HC may exist in an
inactivated form unable to bind targets related to the reduction
of VLCFAs, such as 5-cholesten-3β, 25-diol 3-sulfate (25HC3 S), a
sulfated metabolite of 25-HC that acts in contrast to 25-HC in
the expression of sterol regulatory element binding protein-1
(SREBP-1) and fatty acid synthase (FAS) in hepatocytes.[18]
Regarding studies on mode of action of 25-HC, we
examined whether exogenous addition of 25-CH affects
expression of VLCFA-specific elongase 1 (ELOVL1), which is the
elongase responsible for C26:0 and 26 :1 fatty acid syn-
thesis.[19,20] It has been reported that knockdown[19] or inhibition
[20] of ELOVL1 reduces C26:0 level in X-ALD fibroblasts. As shown
in Figure 3 (Figure S1 for AMN fibroblasts), treatment of CCALD
fibroblasts with 25-HC resulted in decrease of ELOVL1 expres-
sion levels. Therefore, it seems that the effect of 25-HC on
VLCFA levels comes, at least, partially from downregulation of
ELOVL1. Moreover, the knockdown of CH25H, corresponding to
reduced endogenous 25-HC, increased expression of ELOVL1
(Figure 3b). These data suggest that downregulation of CH25H
may lead to reduction of endogenous 25-HC, which can
increase C26:0 levels.
To explore changes of VLCFA levels according to variation
in the key functional group, hydroxy group, some analogues
were evaluated. A dehydrated 25-HC, desmosterol showed
activity, though much less than 25-HC (Figure 4). Analogs of 25-
HC, MSX-101 and MSX-102 were evaluated in CCALD fibroblasts.
Acetylated 25-HC (MSX101) showed similar activity to 25-HC,
but ether analogue (MSX-102) did not reduce C26:0 levels,
which has a tetrahydrofuran moiety for solubility (Figure 4). It
appears that two alcohol moieties or their bioisosteres may take
part in binding targets related to reduction of VLCFAs. Further
investigations are required to clarify the structure-activity
relationship of 25-HC.
Cholesterol and its many metabolites, including desmoster-
ol and 25-HC have been known as liver X receptor (LXR)
ligands.[21] Recently, Liu et al. reported that 25-HC induces
expression of CH25H via activation of LXR.[22] Hence, a widely
used potent LXR agonist, TO901317 was used to explore
whether it could lower VLCFA levels. As shown in Figure 5,
TO901317 significantly reduced VLCFA levels in CCALD and
AMN fibroblasts. In addition, the LXR agonist showed reduction
of VLCFA levels, even in normal human dermal fibroblasts
containing relatively low levels of C26:0.
Figure 2. Changes of C26:0/C22:0 ratio according to CH25H expression level
in CCALD fibroblasts. a) mRNA expression level of CH25H by transfection of
CH25H-EGFP, which was analyzed by quantitative real time PCR. b) C26:0/
C22:0 ratio under ectopic expression of CH25H. c) mRNA expression level of
CH25H by transfection of CH25H or scramble siRNA. CH25H expression was
reduced to approximately 60% after transfection with siRNAs against
CH25H, which was analyzed by quantitative real time PCR. d) C26:0/C22:0
ratio was significantly increased by the knockdown of CH25H. Data are
shown as mean �S.D. from two independent experiments (n=2), **p<0.01,
Student’s t-test.
Figure 3. Relative mRNA expression levels of ELOVL1 under 5 and 10 μM of
25-HC and CH25H knockdown in CCALD fibroblasts. a) Addition of 5 μM and
10 μM of 25-HC for 3 days reduced expression level of ELOVL1. b) The
knockdown of CH25H increased expression level of ELOVL1. The control was
transfected with scrambled siRNA. All mRNA expression levels were analyzed
by quantitative real time PCR. Data are shown as mean �S.D. from three
independent experiments (n=3), *p<0.05, one-way ANOVA with Tukey’s
post-hoc test.
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To our knowledge, it has never reported that LXRs are
involved in biosynthesis of C26:0, although LXRs have been
identified as key regulators of lipid metabolism.[23] Expression of
ELOVL1 is not be effected by LXR agonist T0901317.[24] There-
fore, it seems that 25-HC may act on multiple targets as well as
LXR to reduce VLCFA levels. Further detailed investigations on
mode of action of 25-HC are required. We believe that a novel
therapeutic agent for X-ALD could be discovered from small
molecules derived from 25-HC.
In summary, exogenous addition of 25-HC reduced levels of
C26:0 in CCALD fibroblasts, AMN fibroblasts and oligodendro-
cytes differentiated from iPS cells derived from X-ALD patients.
25-HC was found to downregulate the expression of ELOVL1.
The LXR agonist T0901317 also exhibited a similar effect on
C26:0 levels in X-ALD fibroblasts. Therefore, the activity of 25-
HC may come at least partially from downregulation of ELOVL1
as well as LXR activation. Both of two hydroxy groups of 25-HC
may be involved in target binding. We believe that our results
could contribute to a better understanding of the role of 25-HC
in X-ALD and to finding a therapeutic strategy for the treatment
of X-ALD.
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